Clinical trial
A Multicenter, Prospective, Observational Study to Evaluate Blood Pressure Control Rates and Safety of Ex-one Tablet or Ex-one Plus Tablet in Patients With Essential Hypertension in Real-world Clinical Practice
NCT07930247 is registered in ClinicalTrials.gov with HK inno.N Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Prospective, Observational Study to Evaluate Blood Pressure Control Rates and Safety of Ex-one Tablet or Ex-one Plus Tablet in Patients With Essential Hypertension in Real-world Clinical Practice
- Lead sponsor
- HK inno.N Corporation
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- May 21, 2026
- Completion date
- June 30, 2031
- Enrollment
- 7,525 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Proportion of patients achieving blood pressure control rates at Week 24 after treatment with Ex-one tablets or Ex-one Plus tablets
Blood pressure treatment target of \<140/90 mmHg, according to the 2022 Guidelines for the Management of Hypertension issued by the Korean Society of Hypertension
Lead sponsor's other trials
HK inno.N Corporation, most recent start first.
+98 more trials See the organization page
Similar trials
Same condition (Essential Hypertension) and phase, most recent start first.
+66 more trials See the condition page